Peregrine Pharmaceuticals (PPHM): 50% Upside on this Biotechnology Stock

The patent cliff has positively impacted the valuations of small biopharmaceutical companies due to their acquisition potential. Peregrine Pharmaceuticals (NASDAQ:PPHM) is currently trading at a 50% discount to my estimated target price of $4. I believe the stock will bounce back as the market has still not adjusted for the recent positive news in company disclosures. It is also a major acquisition candidate and I believe it will be a nice fit for Pfizer Inc. (NYSE:PFE) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).

Peregrine Pharmaceuticals (NASDAQ:PPHM)Peregrine Pharmaceuticals (NASDAQ:PPHM) is a biopharmaceutical company focused on the discovery, development, and commercialization of biopharmaceutical products. The company is focused on the development of monoclonal antibodies for the cure of cancer and viral infections.

Pipeline

The company has an interesting pipeline with 3 primary candidates under various phases of clinical trials.

Bavituximab

This candidate is currently in Phase II clinical trials. The drug is being tested in 3 different randomized Phase II clinical trials for the treatment of NSCLC (Non-small Lung Cancer) and pancreatic cancer. Bavituximab is a monoclonal antibody that targets phosphatidylserine and has demonstrated the ability to treat various oncology indications.

Cotara

It is the lead candidate of Peregrine for their Tumor Necrosis Therapy (TNT) and is in Phase II clinical trials. The interim results have been good as the percentage of patients alive at 6 months, 12 months and 24 months were 73%, 38% and 19%, respectively. Moreover, two patients under treatment with Cotara were still alive after 3 years.

PNG650

The company is also in preclinical trial stage for its tumor imaging candidate PNG650. According to company disclosures it has initiated an open label, single center trial at Washington University. The trials will involve 12 healthy subjects which will be given a single dose of the imaging agent.

Valuations

The stock is currently trading at a 55% discount to its mean sell side target price of $4.50 and at a 30% discount to its lowest sell side target price. The stock has traded as high as $5.50 in the last 52 weeks, a 65% upside to current levels. Peregrine lost almost 50% of its value when the company announced in September that there were major discrepancies in the study for its star drug Bavituximab. I have a $4 target price on the stock based on the sell side estimates and past valuations.

Since then the stock has gained some of its value due to the positive announcement by the company that most of the problems indicated with Phase II trial have been resolved, and the drug is all set to enter phase III. According to the company’s announcement the review has found discrepancies with the 1 mg/kg trial and no problems with the 3mg/kg trial. I believe it is only a matter of time before the stock will move back to its value before the negative announcement on Bavituximab ruined its valuations.

Buy or Sell

At these levels the two questions on any investors mind is whether to buy the stock or take advantage of this recovery and get out. I believe at these levels Peregrine is one of the most attractive biotech stocks on the market. The market reacted pretty quickly to the bad news on the discrepancies in Phase II trial of Bavituximab but has still not accounted for the recent positive announcement. The stock is giving more than a 100 percent return on its lowest sell side price target and its pre-September valuations. Keeping in view the large potential in lung cancer drug market and positive Phase II data, I believe Peregrine is a strong buy.

Acquisition Potential

A number of major drug candidates have faced patent expirations in the last couple of years. This has left Big Pharmaceutical players looking for potential acquisition targets to replenish their patent portfolio. I believe Teva and Pfizer are the most likely candidates for acquiring small cap pharmaceutical stocks.

Teva recently announced at its investors meeting that it plans to focus on expanding its drug portfolio rather than returning shareholder wealth. The company has one of the lowest dividend yields in the market and the new management is justifying this dividend yield with a shot at expansion. Teva already has a rich oncology product line with Treanda, Trisenox, Tevagrastim, and Eporatio. Peregrine’s Bavituximab is its leading candidate and would fit in nicely with Teva’s oncology product line.

Pfizer is another major drug company actively looking to replenish its diminishing drug portfolio. The company has almost $22 billion in cash and equivalents and can easily afford Peregrine, valued at $280 million. Pfizer already has a very strong oncology portfolio which will make Peregrine an ideal investment. There will also be a lot of synergy because Pfizer already has one of the best sales and distribution channels for Oncology products.

The article 50% Upside on this Biotechnology Stock originally appeared on Fool.com and is written by Mohsin Saeed.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!